A Phase 1/2 interventional study of Rituximab and N-803 in Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma, sponsored by Altor BioScience. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Altor BioScience (part of ImmunityBio, Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 139 open to participants now, 254 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.
Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 587th largest by enrollment of the 1,377 interventional ones that give a count, is one of 42 that started in 2015, is one of 205 in phase 1/2, and was the 1,077th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →139 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:
Umoja Biopharma · Sites in United States
Ages 18+
University of Arizona · Sites in United States
Ages up to 65
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Paolo Caimi, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,599 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 733 · Phase 2 730 · Phase 3 117 · Phase 4 9
First in 1986; this study’s year is marked. 42 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 43 is close to the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 35 across the 1,377 interventional studies, 91 across the 110 observational. Of the 1,249 that completed or were terminated, 504 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
514 of 1,599 have an industry lead sponsor. The 10 most frequent:
This study is registered under Altor BioScience, one of the names counted as ImmunityBio, Inc.. Under that name alone:
Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
ImmunityBio, Inc. has 2 studies filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
84 of the studies in Lymphoma, Non-Hodgkin with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02972840Phase 3Acerta Pharma BVA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | 2027-02-15 |
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
Add all 84 to your calendar (.ics) → With an account.
Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
The purpose of this study is to evaluate the safety and tolerability, identify the Maximum Tolerated Dose (MTD) or the Minimum Efficacious Dose (MED) and designate a dose level for Phase 2. Also characterize the immunogenicity, pharmacokinetic profile, and biomarker serum levels of N-803 in treated patients.
The effect of N-803 on the peripheral absolute lymphocyte counts and white blood cell counts, the number, phenotype and repertoire of peripheral blood T (total and subsets) and NK cells will be evaluated. In addition, a subset of patients will be evaluated for changes in lymph node immune composition. Anti-tumor responses and survival data will also be collected in this trial.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
This study's enrollment of 43 is close to the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Altor BioScience is the lead sponsor of 15 studies on the registry; none are open to participants now.
First submitted before Altor BioScience became part of ImmunityBio, Inc..
Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
DISEASE CHARACTERISTICS:
confirmed diagnosis of iNHL (Follicular lymphoma grade 1, 2, 3a; marginal zone lymphoma; small lymphocytic lymphoma or lymphoplasmacytic lymphoma) after treatment with at least 1 or more prior rituximab-containing regimens.
:
PRIOR/CONCURRENT THERAPY:
PATIENT CHARACTERISTICS:
Performance Status
Renal Function • (GFR) > 40mL/min or Serum creatinine ≤ 1.5 X
Bone Marrow Reserve
Hepatic Function
Cardiovascular
Pulmonary
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
Biological: Rituximab · Biological: N-803
MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg
Maximum Tolerated Dose level (MTD) is defined as a dose level at which \<2 out of 6 patients experienced Dose Limiting Toxicity (DLT) and that is one level below a dose that was not tolerated. Minimal Efficacious Dose (MED) is defined as a dose level which produces an Absolute Lymphocyte Count (ALC) ≥25,000/μL sustained for 14 days or a total WBC ≥35,000/μL sustained for 14 days among 2/3 or 4/6 of patients. The elevated ALC cannot be attributed to circulating lymphoma cells. Dose levels for N-803 1, 3, 6 μg/kg IV, and 6, 10, 15, 20 μg/kg subcutaneous (SQ) were used to determine the MTD or MED.
Time frame: 9 months
Number of Participants With Treatment Emergent Adverse Events
Treatment Emergent Adverse Event is defined as any AE that begins or worsens in grade after the start of study treatment until 30 days after the last dose of study treatment or end of study period, whichever is later.
Time frame: 30 days after last dose, up to 40 weeks
Overall Response Rate
For Phase 1 and 2, overall response rate (ORR) will be calculated as the ratio of the number of patients who demonstrated response (CR+PR) divided by the number of patients in the Evaluable population. Response and disease progression criteria were defined by the 2007 IHP response assessments for malignant lymphoma.
Time frame: 60 months
| Milestone | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 |
| Completed | 1 | 3 | 1 | 2 | 3 | 3 | 3 | 0 | 0 |
| Not completed | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Failure to meet continuation criteria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Maximum Tolerated Dose level (MTD) is defined as a dose level at which \<2 out of 6 patients experienced Dose Limiting Toxicity (DLT) and that is one level below a dose that was not tolerated. Minimal Efficacious Dose (MED) is defined as a dose level which produces an Absolute Lymphocyte Count (ALC) ≥25,000/μL sustained for 14 days or a total WBC ≥35,000/μL sustained for 14 days among 2/3 or 4/6 of patients. The elevated ALC cannot be attributed to circulating lymphoma cells. Dose levels for N-803 1, 3, 6 μg/kg IV, and 6, 10, 15, 20 μg/kg subcutaneous (SQ) were used to determine the MTD or MED.
| SQ μg/kg | Phase 1 Cohort 7: N-803 - SQ 20 μg/kg |
|---|---|
| MTD or MED of N-803: IV 1, 3, 6 μg/kg, SQ 6, 10, 15, 20 μg/kg | 20 |
Treatment Emergent Adverse Event is defined as any AE that begins or worsens in grade after the start of study treatment until 30 days after the last dose of study treatment or end of study period, whichever is later.
| Participants | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | — | — |
| Phase 2 | — | — | — | — | — | — | — | 16 | 9 |
For Phase 1 and 2, overall response rate (ORR) will be calculated as the ratio of the number of patients who demonstrated response (CR+PR) divided by the number of patients in the Evaluable population. Response and disease progression criteria were defined by the 2007 IHP response assessments for malignant lymphoma.
| percentage of subjects | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 33 (0.8 to 90.6) | 33 (0.8 to 90.6) | 67 (9.4 to 99.2) | 33 (0.8 to 90.6) | 67 (9.4 to 99.2) | 67 (9.4 to 99.2) | 100 (29.2 to 100) | — | — |
| Phase 2 | — | — | — | — | — | — | — | 80 (51.9 to 95.7) | 33 (7.5 to 70.1) |
Collected over All AEs and SAEs were to be reported within 30 days of the last dose of study treatment, regardless of attribution, up to 40 weeks. All deaths were followed during the disease progression and survival follow-up period, up to 42 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 Cohort 1: N-803 - IV 1 ug/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 Cohort 2: N-803 - IV 3 ug/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 Cohort 3: N-803 - IV 6 ug/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | 0/16 (0%) | 3/16 (18.8%) | 16/16 (100%) |
| Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg | 0/9 (0%) | 2/9 (22.2%) | 9/9 (100%) |
| Event | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/16 | 0/9 |
| Cerebrovascular accidentNervous system disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/16 | 0/9 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 1/16 | 0/9 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/16 | 1/9 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/16 | 1/9 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/16 | 1/9 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/16 | 0/9 |
| Sinus node dysfunctionCardiac disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/16 | 0/9 |
| AscitesGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/16 | 0/9 |
| Event | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg |
|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/3 | 2/3 | 3/3 | 2/3 | 0/3 | 1/3 | 1/3 | 4/16 | 0/9 |
| VomitingGastrointestinal disorders | 1/3 | 2/3 | 3/3 | 1/3 | 0/3 | 1/3 | 0/3 | 0/16 | 0/9 |
| ChillsGeneral disorders | 2/3 | 3/3 | 2/3 | 3/3 | 3/3 | 3/3 | 3/3 | 12/16 | 6/9 |
| FatigueGeneral disorders | 1/3 | 2/3 | 3/3 | 1/3 | 1/3 | 3/3 | 3/3 | 7/16 | 6/9 |
| Injection site reactionGeneral disorders | 0/3 | 0/3 | 0/3 | 3/3 | 3/3 | 3/3 | 3/3 | 13/16 | 8/9 |
| PyrexiaGeneral disorders | 2/3 | 2/3 | 2/3 | 1/3 | 2/3 | 3/3 | 3/3 | 13/16 | 9/9 |
| Abdominal painGastrointestinal disorders | 1/3 | 1/3 | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/16 | 0/9 |
| ConstipationGastrointestinal disorders | 0/3 | 1/3 | 1/3 | 1/3 | 1/3 | 2/3 | 1/3 | 2/16 | 2/9 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 1/3 | 1/3 | 1/3 | 2/3 | 3/16 | 1/9 |
| Localised oedemaGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 2/3 | 1/3 | 1/16 | 0/9 |
| Age, Continuous(years) | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 58.0 ± 1.00 | 64.7 ± 7.37 | 69.3 ± 8.39 | 60.0 ± 4.58 | 65.0 ± 10.44 | 68.3 ± 10.21 | 62.0 ± 3.61 | — | — | 63.9 ± 7.28 |
| Phase 2 | — | — | — | — | — | — | — | 59.5 ± 11.39 | 69.1 ± 12.54 | 63.0 ± 12.48 |
| Sex: Female, Male(Participants) | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 — Female | 2 | 2 | 0 | 0 | 2 | 2 | 3 | — | — | 11 |
| Phase 1 — Male | 1 | 1 | 3 | 3 | 1 | 1 | 0 | — | — | 10 |
| Phase 2 — Female | — | — | — | — | — | — | — | 10 | 2 | 12 |
| Phase 2 — Male | — | — | — | — | — | — | — | 6 | 7 | 13 |
| Race (NIH/OMB)(Participants) | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1 — Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1 — Black or African American | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Phase 1 — White | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 0 | 0 | 20 |
| Phase 1 — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 2 — American Indian or Alaska Native | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Phase 2 — Asian | — | — | — | — | — | — | — | 0 | 2 | 2 |
| Phase 2 — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Phase 2 — Black or African American | — | — | — | — | — | — | — | 0 | 1 | 1 |
| Phase 2 — White | — | — | — | — | — | — | — | 14 | 6 | 20 |
| Phase 2 — More than one race | — | — | — | — | — | — | — | 1 | 0 | 1 |
| Phase 2 — Unknown or Not Reported | — | — | — | — | — | — | — | 1 | 0 | 1 |
| Patients with relapse/refractory indolent B cell non-Hodgkin lymphoma(Participants) | Phase 1 Cohort 1: N-803 - IV 1 ug/kg | Phase 1 Cohort 2: N-803 - IV 3 ug/kg | Phase 1 Cohort 3: N-803 - IV 6 ug/kg | Phase 1 Cohort 4: N-803 - SQ 6 ug/kg | Phase 1 Cohort 5: N-803 - SQ 10 ug/kg | Phase 1 Cohort 6: N-803 - SQ 15 ug/kg | Phase 1 Cohort 7: N-803 - SQ 20 ug/kg | Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg | Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | — | — | 21 |
| Phase 2 | — | — | — | — | — | — | — | 16 | 9 | 25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in Dec 2020, 67 months.
Results were first posted in Jul 2024, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nogapendekin alfa inbakicept